
Mundoro Capital gets Centerra Gold backing for C$4.08M placement
Centerra would hold 9.9 per cent of Mundoro after the share issue, which would fund non-partnered exploration and working capital.

The explorer issued 1.2 million shares to vendors and disclosed revised royalties, with a further C$30,000 cash payment due in March.

Centerra would hold 9.9 per cent of Mundoro after the share issue, which would fund non-partnered exploration and working capital.

Nvidia closed 9.26 per cent lower as Bloomberg reported that trend-following funds amplified the Nov. 5 decline.
Preferred equity sits outside reported liabilities, while unrealized bitcoin gains drove the third-quarter profit.
Self-mining output fell to 67 bitcoin from 98 in September, while cloud-mining production was almost unchanged.

MRI-measured muscle fat fraction replaces dynamometry in the 53-boy Duchenne study, with placebo-controlled data expected in Q1 2027.

Free cash outflow narrowed to C$15.5 million as international sales grew, while charges on Canopy USA assets weighed on earnings.

The arrangement is intended to support Aurora component capacity through 2035, but its cost and reserved production volume were not disclosed.

Lease revenue reached US$63 million, but a non-cash warrant adjustment boosted profit and Justified still faces project financing.
Quarterly losses narrowed, but operating income fell and September-end financial statements show US$41.2 million in cash plus restricted funds.
The award adds a technology-development phase, but AST discloses no contract value, funded amount or delivery schedule.
Electric utility earnings rose, while MDU narrowed Bakken East's estimated capital investment to US$2.8B to US$3.1B.
The buyer expects closing in the coming weeks and says future computing demand would be supported by additional generation.
Brooks campus closing requires a credit-backed customer contract and committed financing, while the proposed debt funding remains an expectation.
Quarter-end cash, restricted cash and deposits totalled US$840.6 million before the October CanAdelaar acquisition.
Assays confirm mineralization 500 metres beyond the deposit and higher grades inside Hurricane's southern resource shell.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The Pará court allows studies to continue, while construction and operating licences require further submissions, the company says.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
International COVID-vaccine sales and lower research spending lift earnings, while convertible financing boosts cash and investments.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The proposed common stamp would reduce the number of stamp types from 13 to six, with a Jan. 1, 2028 start date and no company savings estimate.
The cloud operator says US$6 billion of planned funding remains a target, while contracted run-rate revenue awaits commissioning.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The planned sale excludes EES Coke, while DTE’s 2027 earnings baseline assumes a closing earlier than the announced target.

The pipeline operator sets a 2027 net capital spending range of C$6B to C$6.5B and approves Midwest expansions targeting 2030 service.

Shoals holders would receive 1.6931 ARRAY shares per share and own about 65% of the combined company, with closing targeted for early 2027.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Medical-only quarterly results limit year-over-year comparisons as Trulieve reports a US$65 million mortgage repayment after September.

Cash reached US$48.2 million as licensing supported operations, while approaching hemp restrictions threaten current products.

The company identifies its entire Florida retail network, while federal security, inventory and recordkeeping requirements continue.

The psilocybin developer expects its final application submission within two weeks, with a launch targeted for the first half of 2027.